Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial

Blood (2016) 128 (22): 3373.

https://doi.org/10.1182/blood.V128.22.3373.3373

Published: 2016

Journal Articles

CLL Exosome-Derived Y RNA hY4 Induces TLR7/8-Mediated Inflammation and PD-L1 Expression in Monocytes

Franziska Haderk, MSc, Laura Llao Cid, MSc, Murat Iskar, PhD, Ralph Schulz, MSc, Maria Goebel, MD, Jan Duerig, MD, Stephan Stilgenbauer, Marc Zapatka, Peter Lichter, PhD, Martina Seiffert, PhD

Blood (2016) 128 (22): 3217.

https://doi.org/10.1182/blood.V128.22.3217.3217

Published: 2016

Journal Articles

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Maximilian Merz, MD, Hans-Juergen Salwender, MD, Mathias Haenel, MD, Uta Bertsch, MD, Christina Kunz, Thomas Hielscher, Igor W. Blau, MD, Christof Scheid, MDPhD, Elias Karl Mai, MD, Dirk Hose, MD, Bärbel Schurich, Markus Munder, MD, Peter Brossart, MD, Christian Gerecke, MD, Hans Walter Lindemann, MD, Matthias Zeis, MD, Katja C. Weisel, Jan Duerig, MD, Hartmut Goldschmidt, MD

Blood (2015) 126 (23): 4233.

https://doi.org/10.1182/blood.V126.23.4233.4233

Published: 2015

Journal Articles

Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed By Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-Trial (T-PLL2) Conducted By the German CLL Study Group (GCLLSG)

Natali Pflug, MD, Georg Hopfinger, MD, Paula Cramer, MD, Alexandra Schrader, PhD, Nicole Weit, PhD, Rita Meister, Miriam Thiel, Tanja Annolleck, Anne Westermann, Till M Seiler, MD, Thorsten Zenz, MD, Jan Duerig, MD, Jasmin Bahlo, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD, Anna-Maria Fink, MD, Barbara Eichhorst, MD, Michael Hallek, MD, Marco Herling, MD

Blood (2014) 124 (21): 1999.

https://doi.org/10.1182/blood.V124.21.1999.1999

Published: 2014

Journal Articles

Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG

Christof Scheid, MDPhD, Thomas Hielscher, Uta Bertsch, MD, Christina Kunz, PhD, Hans Salwender, MD, Mathias Haenel, Maximilian Merz, Elias Karl Mai, MD, Dirk Hose, MD PhD, Baerbel Schurich, PhD, Markus Munder, MD, Ingo Schmidt-Wolf, MD, Christian Gerecke, MD, Walter Lindemann, MD, Matthias Zeis, MD, Katja Weisel, MD, Jan Duerig, MD, Anna Jauch, PhD, Hartmut Goldschmidt, MD

Blood (2014) 124 (21): 4777.

https://doi.org/10.1182/blood.V124.21.4777.4777

Published: 2014

Journal Articles

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial

Maximilian Merz, MD, Hans Salwender, MD, Mathias Hänel, MD, Uta Bertsch, MD, Christina Kunz, PhD, Thomas Hielscher, Igor W. Blau, MD, Christof Scheid, MDPhD, Elias Karl Mai, MD, Dirk Hose, MD, Baerbel Schurich, PhD, Markus Munder, MD, Ingo GH Schmidt-Wolf, MD, Christian Gerecke, MD, Hans Walter Lindemann, MD, Matthias Zeis, MD, Katja Weisel, MD, Jan Duerig, MD, Hartmut Goldschmidt, MD

Blood (2014) 124 (21): 3475.

https://doi.org/10.1182/blood.V124.21.3475.3475

Published: 2014

Journal Articles

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Blood (2013) 122 (21): 1897.

https://doi.org/10.1182/blood.V122.21.1897.1897

Published: 2013

Journal Articles

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

Blood (2013) 122 (21): 3369.

https://doi.org/10.1182/blood.V122.21.3369.3369

Published: 2013

Journal Articles

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Andreas Bühler, Clemens Wendtner, MD, Michael Hallek, Thomas J. Kipps, MD, PhD, Laura Rassenti, PhD, Graeme Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Duerig, MD, Stephanie A. Gregory, Matt Kalaycio, MD, Therese Aurran-Schleinitz, Livio Trentin, Brendan Purse, Jennie Zhang, Jay Mei, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 1638.

https://doi.org/10.1182/blood.V122.21.1638.1638

Published: 2013

Journal Articles

A New MicroRNA Risk Model for Prediction of Clinical Outcome In Chronic Lymphocytic Leukemia

Holger Nuckel, MD, Crista Ochsenfarth, Ludger Sellmann, MD, Jan Duerig, MD, Ulrich Duehrsen, MD, Ulrich Frey, MD

Blood (2010) 116 (21): 3592.

https://doi.org/10.1182/blood.V116.21.3592.3592

Published: 2010

Journal Articles

Association of HLA-G Haplotype Risk Model with Treatment Free Survival In Chronic Lymphocytic Leukemia Patients

Johanna Kapp, Crista Ochsenfarth, Magdalena Switala, Ulrich Frey, MD, Ludger Sellmann, MD, Jan Duerig, MD, Peter A Horn, MD, Ulrich Duehrsen, MD, Vera Rebmann, PhD, Holger Nuckel, MD

Blood (2010) 116 (21): 2418.

https://doi.org/10.1182/blood.V116.21.2418.2418

Published: 2010

Journal Articles

Abnormal Free Light Chain Ratios in Chronic Lymphocytic Leukemia: A New Prognostic Factor?.

Johannes Matschke, MD, Lewin Eisele, MD, Ludger Sellmann, MD, Ulrich Duehrsen, MD, Jan Duerig, MD, Holger Nückel, MD

Blood (2009) 114 (22): 1237.

https://doi.org/10.1182/blood.V114.22.1237.1237

Published: 2009

Journal Articles

Gene Dosage Effects in B-Chronic Lymphocytic Leukemia with Del 13q14.

Ludger Sellmann, MD, Rene Scholtysik, Holger Nueckel, MD, Tanja Boes, Alexander Carpinteiro, MD, Ulrich Duehrsen, MD, Ludger Klein-Hitpass, Jan Duerig, MD, Ralf Kueppers

Blood (2009) 114 (22): 2640.

https://doi.org/10.1182/blood.V114.22.2640.2640

Published: 2009

Journal Articles

Shorter Telomeres Are Associated with the Unfavourable Chromosomal Aberrations Del 17p and Del 11q in Chronic Lymphocytic Leukemia (CLL)

Ludger Sellmann, MD, Dirk de Beer, Marius Bartels, Holger Nueckel, MD, Ulrich Duehrsen, MD, Jan Duerig, MD, Gabriela Baerlocher, MD, Alexander Roeth, MD

Blood (2008) 112 (11): 3131.

https://doi.org/10.1182/blood.V112.11.3131.3131

Published: 2008

Journal Articles

Significantly Shorter Telomeres in T-Cells of ZAP-70 + /CD38 + Patients with Chronic Lymphocytic Leukemia (CLL): An Important Role of T-Cells in This Subgroup of CLL?.

Alexander Roeth, MD, Dirk de Beer, Holger Nueckel, MD, Ludger Sellmann, MD, Ulrich Duehrsen, MD, Jan Duerig, MD, Gabriela M. Baerlocher, MD

Blood (2007) 110 (11): 1120.

https://doi.org/10.1182/blood.V110.11.1120.1120

Published: 2007

Journal Articles

T-Cells with Extremely Short Telomeres and High Telomerase Activity in T-Cell Prolymphocytic Leukemia (T-PLL): The Ideal Target for Telomerase Inhibition.

Alexander Roeth, MD, Jan Duerig, MD, Heike Himmelreich, Reiner Siebert, MD, Stefanie Bug, Ulrich Duehrsen, MD, Peter M. Lansdorp, MD, PhD, Gabriela Baerlocher, MD

Blood (2006) 108 (11): 497.

https://doi.org/10.1182/blood.V108.11.497.497

Published: 2006

Journal Articles

Association of a Novel Regulatory Polymorphism (-938C>A) in the BCL2 Gene with Disease Progression in Chronic Lymphocytic Leukemia.

Holger Nueckel, MD, Ulrich H. Frey, MD, Ludger Sellmann, MD, Jan Duerig, MD, Ulrich Duehrsen, Winfried Siffert

Blood (2005) 106 (11): 2105.

https://doi.org/10.1182/blood.V106.11.2105.2105

Published: 2005

NARROW

Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial

CLL Exosome-Derived Y RNA hY4 Induces TLR7/8-Mediated Inflammation and PD-L1 Expression in Monocytes

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

A New MicroRNA Risk Model for Prediction of Clinical Outcome In Chronic Lymphocytic Leukemia

Association of HLA-G Haplotype Risk Model with Treatment Free Survival In Chronic Lymphocytic Leukemia Patients

Abnormal Free Light Chain Ratios in Chronic Lymphocytic Leukemia: A New Prognostic Factor?.

Gene Dosage Effects in B-Chronic Lymphocytic Leukemia with Del 13q14.

Shorter Telomeres Are Associated with the Unfavourable Chromosomal Aberrations Del 17p and Del 11q in Chronic Lymphocytic Leukemia (CLL)

Significantly Shorter Telomeres in T-Cells of ZAP-70 + /CD38 + Patients with Chronic Lymphocytic Leukemia (CLL): An Important Role of T-Cells in This Subgroup of CLL?.

T-Cells with Extremely Short Telomeres and High Telomerase Activity in T-Cell Prolymphocytic Leukemia (T-PLL): The Ideal Target for Telomerase Inhibition.

Association of a Novel Regulatory Polymorphism (-938C>A) in the BCL2 Gene with Disease Progression in Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only